Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
Acute stroke afflicts nearly 700,000 patients in the US and is the number 3 cause of death.
Only 2-9% of this large number is treated with t-PA if they arrive within 4.5 hours. An
equally small percentage of patients with large vessel occlusion undergo thrombectomy.
The thrombectomy patients may or may not receive t-PA. Some of these patients rarely receive
intravenous GPIIB/IIIa inhibitors. Many lines of evidence suggest that GP IIb/IIIa
inhibitors, a class of FDA approved potent platelet inhibitors that have been used
extensively along with heparin for acute coronary syndromes (heart attacks) and unstable
angina (chest pain), may be safe enough to give in these circumstances.